SPRB · Spruce Biosciences, Inc. · Metrics
$44.18
-0.97 (-2.15%)
At close · Oct 26
Return incl. dividend (before tax)
Market Cap
$127.58M
Shares
2.87M
Volume · Oct 26
47.49K
Avg daily vol (3M)
80.17K
SPRB metrics
62 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$45.15
Market cap
$127.58M
Price action
20 metricsPrice change (1W)
+13.9%
Price change (30D)
-5.0%
Price change (3M)
+4.8%
Price change (6M)
-17.0%
Price change (YTD)
-48.2%
Price change (1Y)
-65.2%
Trailing year
Price change (5Y)
—
52-week high
$133.24
52-week low
$38.98
Change from 52-week high
-66.1%
Change from 52-week low
+15.8%
Annualized volatility
85.3%
Annualized volatility (3M)
64.5%
Beta
1.8
RSI (14D)
49.2
Price vs SMA 50
-10.9%
Price vs SMA 200
-20.2%
Avg volume (3M)
80,167
Relative volume
0.9
Average dollar volume
$4.06M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
2.87M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.5
reciprocal yield 64.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-39.6%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2024-11-12
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$47.83M
Net income (TTM)
−$51.35M
Trailing 12 months
Diluted EPS (TTM)
$-39.00
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+311.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-61.3%
Return on assets
-49.9%
Debt / equity
0.1
Current ratio
9.2
EBITDA (TTM)
−$46.94M
Free cash flow (TTM)
—
Quick ratio
9.2
Interest coverage
-26.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$89.20M
Latest balance sheet
Cash & equivalents
$96.30M
Total assets
$102.85M
Total debt
$7.09M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$42.62M
Capital expenditures (TTM)
—
R&D (TTM)
$28.85M
SG&A (TTM)
—
Stock compensation (TTM)
$3.67M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
64
13F filer change QoQ
+32
Institutional ownership
69.8%
Conviction holders (share of 13F filers)
1.6%
Crowding (high-turnover and private-fund holders)
49.4%
Private-fund adviser ownership
40.3%
Active holders' share change QoQ
+119.8%
Holder tenure
2.3
Price vs estimated holder cost
-18.2%
Ownership (registered funds)
1 metricsIndex-fund ownership
8.5%
Short interest
3 metricsShort interest
15.0%
Latest settlement · 4.5 days to cover
Days to cover
4.5d
Short-squeeze score
66 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—